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Background: Obesity, characterized by low grade inﬂammation, induces adipose tissue macrophage (ATM) inﬁl-
tration inwhite adipose tissue (AT) in both humans and rodents, thus contributing to insulin resistance. Previous
studies have shown altered prolactin secretion in obesity, however, studies linking ATM inﬁltration and prolactin
(PRL) secretion to the pathogenesis of the metabolic syndrome, obesity and diabetes are lacking.
Methods/Results: In vivo, qPCR andWestern blot analysis demonstrated that prolactin expression was increased
in AT of obese rats and also in human AT from obese, obese pre-diabetic and obese diabetic compared to lean
counterparts. Immunohistochemistry of obese rat and human AT sections demonstrated a speciﬁc expression
of prolactin inmacrophages. In vitro, we demonstrated that hyperglycemia and inﬂammation stimulatedmacro-
phages (human THP-1 cell line and sorted rat ATM) to express PRL, when challenged with different glucose
concentrations with or without IL1β. In in vivo and in vitro experiments, we assessed the expression of Pit-1
(PRL-speciﬁc transcription factor) and found that its expression was parallel to PRL expression.
Conclusions: In this study, we show that rodent and humanmacrophages synthesize prolactin in response to in-
ﬂammation and high glucose concentrations.
General signiﬁcance: Our data shed new light on the potential role of macrophages in the physiopathology of
diabesity via the PRL expression and on its expression mechanism and regulation.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Obesity is amajor health problemwith increasing prevalenceworld-
wide. Since 1980, obesity has more than doubled. Estimations report
2.8 million deaths as a result of being overweight or obese. The develop-
ment of type 2 diabetes in obese patients led to the term diabesity.
Obesity is predisposing to a variety of age-related inﬂammatory dis-
eases including insulin resistance, type 2 diabetes, atherosclerosis, oste-
oarthritis, fatty liver diseases and cancer [1]. One key feature of obesityo conﬂict of interest.
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ights reserved.is a chronic low-grade inﬂammation induced by various inﬂammatory
mediators [2]. This inﬂammation occurs in the expanding adipose tissue
and is associated with inﬁltration of immune cells like macrophages,
lymphocytes and mast cells.
In mammals, adipose tissue includes both white adipose tissue
(WAT) and Brown adipose tissue (BAT) implicated in lipid storage and
thermogenesis respectively. Since 1993, WAT is no longer considered
just as a storage tissue but as an endocrine organ controlling numerous
physiological and pathological processes. Adipose tissue is com-
posed of mature adipocytes and other cell types (i.e. cells of the
haematopoietic lineage like macrophages, endothelial cells, ﬁbroblasts
and preadipocytes) present in the stroma vascular fraction (SVF) [3–5].
Tissue macrophages are composed of different subpopulations exerting
different physiological properties. Two well-known subtypes: M1
(classically activated macrophages) with pro-inﬂammatory properties,
and M2 (alternatively activated macrophages) with anti-inﬂammatory
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dynamic inter-conversion depending on the encountered environment
[8]. Obesity increases tissue inﬁltration of macrophage [9] and polariza-
tion towards the M1 phenotype [10–12].
Adipose tissue is able to release hundreds of biologically active
molecules grouped under the term “adipokines” that can be cytokines,
chemokines or hormones. These adipokines, released also by the cells
of the SVF, affect appetite and satiety (leptin), glucose and lipid metabo-
lism (adiponectin, visfatin, resistin), blood pressure (angiotensinogen),
inﬂammation (TNFα, IL1β, IL6, CCL2) and immune functions (prolactin).
Prolactin (PRL) is a polypeptide hormonemainly secreted by the pi-
tuitary gland and by the placenta in rodents, whereas in humans, its ex-
pression is observed in many extra-pituitary sites like mammary gland,
skin, decidua, prostate, immune cells (B- and T-lymphocytes, natural
killers and macrophages) and brain [13,14]. This wide-spread expres-
sion partially explains its involvement in various processes like repro-
duction, behavior, immune modulation and metabolism. Aside from
gestation where PRL favors the development of the mammary gland,
PRL is implicated in the modulation of the innate and adaptative im-
mune system by stimulating the secretion of cytokines and the expres-
sion of cytokine receptors [15,16]. PRL expression is under the control of
the pituitary transcriptional factor-1 (Pit-1 also known as Pou1f1)
which is of paramount importance for the expression of PRL in the pitu-
itary gland [17]. Pit-1 is one of the members of the POU homeodomain
family [18,19]. The action of Pit-1 on PRL transcription has been exten-
sively studied in pituitary cells [20]. In extra-pituitary tissues, Pit-1 is
binding to an alternative promoter to induce the PRL expression. The
stimuli inducing Pit-1 expression and action on PRL expression are
still unclear and need to be clariﬁed.
Prolactin regulates also energy balance. Recently, a prolactinoma
has been associated with obesity and its associated perturbations like
metabolic syndrome and insulin resistance [21,22]. Studies demonstrat-
ed that patients [23–25] and animals [26,27] with hyperprolactinemia
weremore prone to gain weight. Prolactin seems to be released propor-
tionally to the quantity of fat mass in obese patients [28]. Weight loss in
these patients resulted in a decrease in the 24 h-prolactin release [29].
The mechanisms implicated in this phenomenon are still poorly un-
derstood and need further investigations. The normalization of PRL
levels by dopamine agonists like bromocriptine was associated with
weight loss [23,25,30]. The reduction of prolactinemia, via the use of
dopamine-D2 receptor agonists like bromocriptine or cabergoline, sur-
prisingly ameliorated the glycemia of type 2 diabetic patients without
increasing insulin release [31–33]. Prolactin expression/secretion is
regulated by different stimuli provided by the environment. In the im-
mune system, PRL is thought to act as a locally produced cytokine
with relevance for immune regulation and modulation of T- and B-cell
function. Nevertheless, the molecular mechanisms regulating PRL
expression in the immune system and the factors implicated are still
not fully understood.
We demonstrate in this paper, that human and rat macrophages
synthesize prolactin in response to inﬂammation and high glucose
concentrations as can be encountered during obesity and diabetes.
Moreover, we observed that PRL transcription is mediated, in human
and rat macrophages, by Pit-1 which expression is also dependent on
inﬂammation and glucose concentrations. Our data are bringing new
light on the potential role of resident adipose tissue macrophages in
maintaining/worsening inﬂammation and obesity and on the mecha-
nism leading to prolactin secretion in response to hyperglycemia and
inﬂammation.
2. Materials and methods
2.1. Animals
Wistar rats (Janvier SAS (Le Genest Saint Isle, France)) received food
and water ad libitum and were maintained at 25 °C with 10–14 hdark–light cycle. Experimental procedures were performed after ap-
proval by the ethics committee of the Université de Lille 2.
Animals of the obese group (OB group) were fed an obesogenic diet
(Western RD Diet, Special Diet Service, Argenteuil, France) composed of
50% of carbohydrate (mainly sucrose), 21.4% of crude fat, 17.5% of
proteins, 4.1% of ash and 3.5% of ﬁbers for 4 months to induce obesity.
During the feeding period, animals were weighed twice a week to
follow weight gain. At the end of the period, animals were sacriﬁced
under anesthesia and visceral adipose tissue was collected. Tissues
were conserved in RNA later (Sigma Aldrich) for subsequent RNA ex-
traction and pulverized in protein lysis buffer (RIPA) for protein analysis
before being stored at−80 °C.
For the diabetic group (STZ group), the animals received a single
dose of Streptozotocin (STZ) (Sigma-Aldrich Chimie, France) (65 mg/kg
dissolved in 0.1 M citrate buffer pH4.5) by intraperitoneal injection. The
control group received a single injection of an equivalent volume 0.1 M
citrate buffer pH4.5.
For all groups, trunk blood samples were collected in heparinized
tubes and centrifuged to extract the plasma. Before use, samples were
stored at−20 °C.
2.2. Rat and human primary adipose tissue macrophages (ATM) isolation
Adipose tissues coming from control, STZ andOB animalswere proc-
essed. Brieﬂy, perigenital and perirenal adipose tissues were collected,
washed by a rapid immersion in 70%, ethanol minced with sterile
scissors, centrifuged to remove redblood cells and digested by a collage-
nase solution (1 mg/ml of collagenase P (Sigma) in Hank's Balanced
Sodium Salt (HBSS) (Life Technologies, Saint Aubin, France)) at 37 °C
waterbath. After 15 min, digestion was stopped by adding HBSS
supplemented with 5% Bovine Serum Albumin (BSA) (HBSS-BSA)
(Sigma Aldrich). Samples were passed through a sterile strainer
(70 μm) to remove undigested tissue. Three consecutive washes
were done to remove the ﬂoating adipocytes and to collect the stro-
mal fraction constituted mainly of preadipocytes and red and white
blood cells. The SVF was treated with red blood cell lysis solution
(155 mmol/l NH4Cl, 10 mmol/l KHCO3 and 90 μmol/l EDTA) for
3 min on ice and washed two times in HBSS. To collect all ATM, the
CD68 antibody (AbDSerotec, Colmar, France), a pan macrophage
marker was used. Dissociated cells were stained for 1 h at 4 °C with
a mouse CD68 antibody under constant shaking. After 3 washes in
PBS-EDTA (1 mmol/l), anti-mouse magnetic beads (Miltenyi Biotec,
Paris, France) were added to the cells for another 30 min at 4 °C
under constant shaking. Cells were washed again 3 times and sorted
with the AutoMACS (Miltenyi Biotec). Following sorting, cells were
washed 3 times in HBSS-BSA and splitted in 24-well culture plate
for culture and treatment.
For human ATM, the sorting procedure has been described elsewhere
[34]. ATM were collected from adipose tissue (visceral fat) coming from
obese women; all patients were non diabetic (glycemia b 6 mmol;
HbA1c b 6%). Patient characteristics are summarized in Table 1.
2.3. Human adipose tissue and serum
Visceral adipose tissue (n = 24) was obtained from diabetic and
non-diabetic morbidly obese patients undergoing bariatric surgery at
the University Hospital of Lille (Lille, France). This study was approved
by the ethics committee of the CHRU of Lille under the Atlas Biologique
de l'Obésité Sévère (ABOS) framework. None of the patients had clinical
symptoms of systemic inﬂammation and all gave written informed
consent. Patients used in this study were age-matched and 3 male and
3 females were selected per group to evaluate sexual dysmorphism
effect. Patient characteristics are summarized in Table 2.
Sera were collected from obese (n = 18) and lean (n = 6) subjects
and prolactin concentration was measured by ELISA (Eurobio, Les Ulis,
France).
Table 1
Characteristics of visceral fat samples used to collect ATM.
Characteristics OB1 OB2 OB3 OB4 OB5
Age (years) 24 37 43 19 46
Gender F F F F F
BMI (kg/m2) 54.8 55.8 45.6 45.2 48.7
Weight of AT collected (g) 42 57 38 100 48
ATM in VST
% ATM 6.3 9.5 11.5 12.5 13.3
% ATM/weight AT 0.15 0.17 0.30 0.13 0.28
Co-morbidities
Diabetes – – – – –
Hypertension – – – – –
Hyperlipidemia – – – + –
Sleep apnea – – – – +
Medication for
Diabetes – – – – –
Hypertension – – – – –
Hyperlipidemia – – – – –
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The human monocytic cell line (THP-1), (LGS Standards, Molsheim,
France) was grown in RPMI 1640 supplemented with 10% fetal bo-
vine serum (FBS), 100 U/ml penicillin, 100 μg/ml streptomycin,
2 mM L-glutamine and 30 mM glucose in an air–CO2 (95:5) atmo-
sphere at 37 °C. Cells were seeded in a 6-well plate until reaching
conﬂuence. Conﬂuent cells were treated for 3 days with Phorbol 12-
Myristate 13-Acetate ((PMA), Sigma Aldrich) (100 μM) to induce dif-
ferentiation of ﬂoating monocytes into adherent macrophages. Follow-
ing differentiation, cells were washed two times with PBS and treated
for 24 h with medium containing different glucose concentrations
(5.5, 11 or 30 mM) supplemented or not with recombinant human
interleukin-1beta (IL1β) (100 ng/ml) (Sigma Aldrich).
Rat adipose tissuemacrophageswere cultured in RPMI 1640 supple-
mented with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin,
2 mM L-glutamine and 5.5 mM glucose in an air–CO2 (95:5) atmosphere
at 37 °C. After 1 day of recovery, ATM were treated with mediumTable 2
Characteristics of fat samples used for prolactin evaluation.
Characteristics Lean OB
Age (years) 54 ± 2.2 45 ±
Patients per group 6 6
Gender, number
male 3 3
female 3 3
BMI (kg/m2) 24.3 ± 0.6 44.9 ±
Fasting Glycemia (mM) 4.3 ± 0.4 5.0 ±
HbA1c (%) 5.45 ± 0.05 5.25 ±
OGTT (glycemia at 2 h (mM)) 3.48 ± 0.4 6.08 ±
Co-morbidities
Hyperlipidemia 0/6 2/6
Hypertension 0/6 4/6
Sleep apnea 0/6 5/6
Medication for
Diabetes
Metformin – –
Insulin – –
Sulfonylurea – –
Hypertension – 2/6
Hyperlipidemia – 2/6
Each group was composed of 3 males and 3 females. Patients in each group were age-matched
age and HbA1c between all the groups.
⁎ p b 0.001 OB, OBPreD, OBD vs lean.
⁎⁎ p b 0.001 OB, OBPreD vs OBD.
⁎⁎⁎ p b 0.001 OBPreD and OBD vs lean.
⁎⁎⁎⁎ p b 0.05 OB vs OBPreD.containing different glucose concentrations (5.5, 11 or 30 mM) supple-
mented or not with recombinant rat IL1β (100 ng/ml) (Sigma Aldrich).
2.5. RNA extraction and cDNA synthesis
Total RNA was isolated from rodent and human adipose tissues,
adipose tissue macrophages and THP-1 cells with TRIZOL, according
to the manufacturer's instructions (Life Technologies). RNA concen-
trations were evaluated by measuring absorbance at 260 nm with a
spectophotometer (NanoDrop, Thermo Fisher Scientiﬁc, France). RNA
quality was evaluated with bioanalyzer 2100 (Agilent Technologies).
Only samples reaching a RNA Integrity Number (RIN) N8 were used
for qPCR analyses.
500 ng of total RNA was used for retro-transcription using oligo-
d(T) to selectively amplify mRNA. cDNAs were synthesized with First
Strand cDNA Synthesis kit (Thermo Fisher Scientiﬁc, Illkirch, France)
as described by the manufacturer.
2.6. Gene expression analysis
The RT-qPCR experiments and calculations using the 2 − ΔΔCt
method were performed as previously described [35]. Data were
normalized to housekeeping genes (hprt (Hypoxanthine-guanine
phosphoribosyltransferase) for rat orβ-actin for human). The -RT controls
tested for the considered genes assessed the absence of genomic DNA
contamination for each sample. Primers (Table 3) have been designed
to split an exon–exon junction to avoid genomic DNA ampliﬁcation.
2.7. Western blotting
Adipose tissue, ATM and THP-1 proteins (40 μg) were resolved in a
15% SDS-PAGE gel under reducing conditions. After separation, proteins
were transferred to nitrocellulose membranes (0.2 μm; Millipore,
Molsheim, France). The membrane was blocked in TBS-0.1% tween
(TBST) and 5% nonfat dry milk, followed by an overnight incubation
with primary antibodies in TBST and 5% BSA (goat anti-prolactin
(1:1000 (Santa CruzBiotechnology, Heidelberg, Germany)) and as a load-
ing control mouse anti-beta actin (1:5000 (Sigma Aldrich, France))). TheOBPreD OBD
1.6 50 ± 2.0 49 ± 4.0
6 6
3 3
3 3
2.9⁎ 47.2 ± 3.2⁎ 49.7 ± 3.1⁎
0.4 5.8 ± 0.2⁎⁎ 12.6 ± 1.4⁎⁎
0.10 5.98 ± 0.08 10.45 ± 0.46
0.4⁎⁎⁎⁎⁎⁎ 9.38 ± 0.2⁎⁎⁎⁎⁎ 18.8 ± 1.4⁎⁎⁎
2/6 3/6
3/6 3/6
3/6 4/6
– 5/6
– 2/6
– 3/6
3/6 3/6
2/6 3/6
. No sexual dysmorphism was observed. No signiﬁcant differences have been observed for
Table 3
Primers used for quantitative PCR on rat and human samples with Genbank accesion number.
Gene Genbank Forward (5′-3′) Reverse (5′-3′)
h PRL NM_000948.5 ACCAGGAAAAGGGAAACGAATGCC CGTTGCAGGAAACACACTTCACCA
h Pit-1 NM_001122757.1 CAACGTTGGGAAACACAGCA CAAGGGGTTAAACTACCTGCCA
h β-actin NM_001017992 CATGTACCCAGGCATTGCT ACTCCTGCTTGCTGATGCA
PRL NM_012629.1 GGGAGGGGAAGAGGATGCCTG GTGTCCCTGCTTTCCGGGCTG
Pit-1 NM_013008.3 GAGATCATGCGGATGGCTGA ATGGCTACCACAGGCAAGTC
hprt NM_012583.2 ACCTGGGACCGAGACATGTA GAAGATGGTGTGCTCATTGC
h PRL: human prolactin; h β-actin: human β-actin; h Pit-1: human pituitary-speciﬁc transcription factor.
Prl: rat prolactin; Pit-1: Pituitary-speciﬁc transcription factor; Hprt: rat Hypoxanthine phosphoribosyltransferase.
Fig. 1. Evaluation of prolactin expression in the adipose tissue of obese and lean rats and
humans. qPCR analysis showed a 12 fold increase in the expression of prolactinmRNA be-
tween AT from lean and obese in rodents. The expression in the AT of obese animals was 2
times higher than in the pituitary gland. For humans, the prolactin expressionwas 2 times
higher in adipose tissue from obese (compared to lean control). Results aremeans ± sem of
5 independent experiments, *p b 0.05; **p b 0.01; ***p b 0.001; ANOVA with Bonferroni
correction.
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perature with infrared ﬂuorescent-conjugated secondary antibody
(1:20,000, Li-Cor, ScienceTec, Courtaboeuf, France) in the dark. The
signal was detected with the Odyssey CLx scanner (Li-Cor, ScienceTec)
and pixel density quantiﬁed using ImageJ.
2.8. Prolactinemia
Concentration of circulating prolactin was measured in sera of
control and obese rats using rat prolactin ELISA kit (Cusabio, Wuhan
Hubei, China). For human samples, prolactin was assayed by ELISA
(Eurobio, Courtaboeuf, France) in lean, obese, obese prediabetic and
obese diabetic patients. Each of the experimental groups was constituted
of 6 individuals. Samples were processed following the manufacturer's
instructions.
2.9. Immunohistochemistry
Tissue samples were ﬁxed in 4% PFA for 24 h and embedded in
parafﬁn. After deparafﬁnation, sections were treated with methanol
supplemented with 3% hydrogen peroxide to inhibit endogenous
peroxidase. Antigen retrieval was performed by heating the sections
for 5 mins at 96 °C in citrate buffer pH 6 supplemented with 0.1%
Tween. After a cooling period of 20 mins, sections were incubated with
mouse monoclonal anti-rat or anti-human CD68 (1:500; AbDSerotec).
All sections were incubated with Alexa 488-conjugated anti-goat
and Alexa 594-conjugated anti-mouse antibodies (Life Technologies,
France). Nuclei were counterstained with mounting medium containing
DAPI (Eurobio, Les Ulis, France). After staining, counting have been real-
ized in lean and obese (for rat) and in lean and obese diabetic patients
(for human) to evaluate the quantity of adipose tissue inﬁltrating
macrophages.
2.10. Statistical analysis
Otherwise stated, all resultswere analyzedwith ANOVA followed by
Bonferroni post-tests with GraphPad Prism (GraphPad Software, San
Diego, CA). The results were reported as means ± sem. For human
sample analysis, statistical differences between groups were analyzed
by Mann–Whitney rank-sum test. Differences of p b 0.05 were consid-
ered as statistically signiﬁcant.
3. Results
3.1. Prolactin expression is increased in the adipose tissue of obese rats
and humans
We compared the expression of PRL in different tissues in rats and
humans (Fig. 1A and B). In the rat, we used the pituitary gland as a
positive control for PRL expression. The expression of PRL was higher
in the adipose tissue from obese rats compared to pituitary and adipose
tissue from control animals (p b 0.01 and p b 0.001 respectively). As
shown in Fig. 1B, in human adipose tissue, the expression of PRL was
signiﬁcantly higher (p b 0.01) in obese vs0020lean patients.3.2. Prolactin is expressed by macrophages in the adipose tissue of
obese rats
To identify which cells in adipose tissue express PRL, immunoﬂuo-
rescent staining was performed on rat adipose tissue sections from
lean and obese animals. In Fig. 2A, histological analyses of obese rat
adipose tissue identiﬁed macrophages as cells expressing PRL. With
the development of obesity and the subsequent inﬂammation, macro-
phages inﬁltrate adipose tissue (CD68 staining in red and PRL staining
in green). In lean animals, few macrophages inﬁltrated the adipose tis-
sue (Fig. 2B) and corresponding PRL staining was weak.
In the AT of obese rats, most of the macrophages were localized at
the junctions of two or more adipocytes (Fig. 2A). Crown structures
can be identiﬁed only in obese adipose tissue (Fig. 2C). Counting of
macrophages on AT sections revealed a signiﬁcant difference between
quantities of inﬁltrating macrophages in lean compared to obese
(2 ± 0.4 vs 34.6 ± 4.3 respectively, p b 0.01).
3.3. Prolactin is expressed by ATM following inﬂammation
Obesity is often accompanied by insulin resistance predisposing to
type 2 diabetes which is diagnosed by elevated blood glucose concen-
tration. To identifywhich stimuli induce the expression of PRL inmacro-
phages, ATM were sorted from adipose tissue of lean animals and
treated with different glucose concentrations for 24 h. We observed
that increasing glucose concentrations (5.5, 11 mM and 30 mM,
*p b 0.05) 5–10 times increased the expression of PRL in the macro-
phages (Fig. 3A). IL1β, a well-known pro-inﬂammatory cytokine, also
enhanced PRL expression in macrophages incubated with for 5.5 and
11 mM glucose demonstrating an additive effect of inﬂammation
Fig. 2. Adipose Tissue Macrophages (ATM) express prolactin in obese animals. Immunohistochemistry for prolactin (green) and CD68 (red), a pan-macrophage marker performed in the
adipose tissue of lean (B, D) vs obese (A, C) animals showed a clear expression of prolactin by themacrophage only in the adipose tissue of obese animals. Crown structures can be observed
only in obese animals. Magniﬁcation ×200 (A and B); Magniﬁcation ×400 (C and D).
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further amplify the response showing a saturation of the system.
Western blot analysis demonstrated that increasing glucose concen-
trations signiﬁcantly induced PRL protein levels (p b 0.01) (Fig. 3B).
Combined treatment with glucose plus IL1β also induced PRL expres-
sion signiﬁcantly at 11 and 30 mM (p b 0.001). As previously observed
atmRNA level, the combination of 30 mMglucose supplemented or not
with IL1β induced a lower PRL expression than 11 mM, highlighting a
possible saturation of the system.Fig. 3. Prolactin expression bymacrophages is activated in vitro in the rat adipose tissuemacrop
tion of prolactin expression dependent on glucose concentration. Treatment with IL1βwas also
effect when added to high glucose containingmedium. (B) As observed at themRNA level,Wes
concentrations of glucose. The additive effect of IL1β and glucose on prolactin synthesis coul
***p b 0.001 vs 5.5 mM;)o()o(p b 0.01 vs 5.5 + IL1β; ANOVA with Bonferroni correction.3.4. Prolactin is expressed in human macrophages under
inﬂammatory conditions
To conﬁrm the observations made in rodent adipose tissue, analysis
of adipose tissue from lean and obese patients and ATM from obese pa-
tients were carried out. As previously observed in Fig. 1B, a 4.5 fold
higher expression of PRL was observed in tissues from obese diabetic
compared to lean individuals. To investigate if hyperglycemia had an
additive effect on obesity, we evaluated PRL expression at the mRNAhages by hyperglycemia and inﬂammation. (A) qPCR analysis revealed a signiﬁcant induc-
capable of inducing prolactin expression by the macrophages demonstrating an additive
tern Blot analysis and quantiﬁcation revealed prolactin synthesis in response to increasing
d also be observed. Results are means ± sem of 5 independent experiments; **p b 0.01,
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and obese diabetic patients (OBD). As shown in Fig. 4A, C and D, obesity
with diabetes (called Diabesity) resulted in a higher PRL expression. It
should be pointed out that obese diabetic patients received daily anti-
diabetic treatment (mainly metformin alone or in combination with
insulin) potentially weakening the hyperglycemia effects. As PRL was
expressed by macrophages, we evaluated the expression of PRL in
ATM from morbidly obese patients. As control, we used Monocyte-
Derived Macrophages (MDM) coming from the same patients. We
observed 2000 times higher expression of PRL in ATM compared to
MDM (Fig. 4B).
As previously observed for rat adipose tissue, immunohistochemis-
try performed on human adipose tissue samples coming from lean
(Fig. 5A), obese (Fig. 5B), obese prediabetic (Fig. 5C) and obese diabetic
(Fig. 5D) subjects demonstrated increased macrophage inﬁltration in
obese compared to lean patients (44.2 ± 6.8 and 1.8 ± 0.5% for obese
diabetic and lean respectively, p b 0.01). Prolactin expression (green
staining) in macrophages (CD68 positive, red staining) was strongest in
adipose tissue from obese prediabetic and obese diabetic (Fig. 5C and D).
To conﬁrm that the same mechanism was occurring in human cells
as observed in rat, THP-1 cells were studied. As shown for rat ATM,
culturing THP-1 cells, inmediawith different glucose concentrations re-
sulted in an increase of PRL expression at the mRNA and protein levels,
an effect further enhanced by IL1β treatment (Fig. 6A & B). For all glu-
cose concentrations evaluated, adding IL1β increased PRL mRNA levels
2 times.
3.5. Obesity increases prolactinemia
We evaluated the level of serum prolactin (prolactinemia) in obese
rats, using as a positive control, sera from rat at the 20th day of gestationFig. 4. Evaluation of prolactin expression in human adipose tissue, Adipose Tissue Macropha
(A) qPCR analysis of lean (n = 6) and obese subjects with different glycemic status (Obese (OB
a signiﬁcative increase in prolactinmRNA for obese (independent of their glycemic status) comp
and MDM (□) from 5 different obese patients. For each subject, ATM and MDM were collected
prolactin expression by the visceral adipose tissue of lean and obese patients with different gly
(OBD) (n = 6)). Prolactin expression is signiﬁcantly increased in obese patients compared to
means ± sem of 6 independent experiments for each of the experimental groups considered,(peak of circulating prolactin). We observed a signiﬁcant increase in
obese animal vs lean animal sera (p b 0.05) (Fig. 7A). Moreover, PRL
concentrations were increased in sera from obese, obese prediabetic
and obese diabetic patients indicating that obesity complicated by dia-
betes exacerbates prolactinemia (p b 0.05) (Fig. 7B).
3.6. Pit-1 expression is regulated by inﬂammation and hyperglycemia
We compared the expression of Pit-1, the PRL transcription factor, in
rat ATM (Fig. 8A) andTHP-1 cells (Fig. 8B) treatedwith different glucose
concentrations combined or not with IL1β. As previously observed for
PRL expression, we observed a signiﬁcant increase of Pit-1 expression
(*p b 0.05, **p b 0.01) 10–20 times after the glucose treatment (Fig. 8A
& B). IL1β enhanced Pit-1 expression in THP-1 cells incubated with all
tested glucose concentrations demonstrating an additive effect of inﬂam-
mation (IL1β) on glucose (Fig. 8B). For rat macrophages, IL1β treatment
didn't induce an enhancement of Pit-1 expression (Fig. 8A). In human
adipose tissue samples from lean, obese, obese prediabetic and obese
diabetic subjects, we observed a signiﬁcant increase of Pit-1 expression
in obese (p b 0.05) and obese prediabetic (p b 0.01) compared to the
lean subjects. For the obese diabetic, we observed a 300 times increased
expression compared to the lean counterparts (p b 0.001).
4. Discussion
In the present study, we show that macrophages are a source of
prolactin expression and that this expression is enhanced in pathophys-
iological conditions such as obesity and diabetes. We show in vitro that
high glucose concentrations and IL1β (mimicking the combination of
hyperglycemia and inﬂammation) enhanced the expression of PRL in
macrophages.ges (ATM) and Monocyte-Derived Macrophages (MDM) from obese and lean subjects.
) (n = 6), Obese Pre Diabetic (OBPreD) (n = 6); Obese Diabetic (OBD) (n = 6)) revealed
ared to lean. **p b 0.01, ***p b 0.001. (B) qPCR analysis of prolactin expression inATM (■)
for comparison. ***p b 0.001 vs MDM. (C–D) Western blot analysis and quantiﬁcation of
cemic status (Obese (OB) (n = 6), Obese Pre Diabetic (OBPreD) (n = 6); Obese Diabetic
lean *p b 0.05; **p b 0.01. β-actin was used to assess equal protein loading. Results are
ANOVA with Bonferroni correction.
Fig. 5. Prolactin expression by Adipose Tissue Macrophages in Lean, Obese (OB), Obese PreDiabetic (OBPreD) and Obese Diabetic (OBD) humans. Immunohistochemistry for pro-
lactin (green) and CD68 (red), performed in the adipose tissue of lean (A), obese (B), obese prediabetic (C) and obese diabetic (D) patients showed a clear increased expression
of prolactin by the macrophage in the adipose tissue of obese individuals. An enhancement of prolactin expression was observed in obese prediabetics (C) and obese diabetics
(D). Magniﬁcation ×200 (A, B, C, D); magniﬁcation ×400 (picture included in picture A).
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additive effect on prolactin expression by the macrophages both in
adipose tissue macrophages in rodents and in monocyte/macrophage
human cell line THP-1, human adipose tissue and human ATM.
Obesity is formerly considered as the expansion of the adipose tissue
mass associated with the development of a chronic low grade inﬂam-
mation located in the adipose tissue but spread in the whole organism
by the blood ﬂow. This inﬂammation, linked to insulin resistance but
also to other obesity-related morbidities, is promoting macrophageFig. 6. Humanmonocyte/macrophage cell line THP-1 expresses prolactin in vivo when treated
prolactin mRNA expression demonstrated an increased expression after high glucose treatme
**p b 0.01. (B) Western blot analysis of prolactin expression and quantiﬁcation. β-actin was u
experiments, ANOVA with Bonferroni correction.inﬁltration of the adipose tissue [36,37]. Macrophage density is directly
proportional to the level of obesity [9]. In the present study, we
conﬁrmed in rats and humans that there are increasing quantities of
macrophages in the fat of obese individuals. Inﬁltrating macrophages
are in direct contact with the cytokines/chemokines released by the
adipocytes. A recently published study on transgenic rats expressing
the human prolactin gene demonstrated that, in a model of experimen-
tal inﬂammation by thioglycollate injection, prolactin expression is
highly increased in peritoneal macrophages [38]. We observed, in ourwith different glucose concentrations supplemented or not with IL1β. (A) qPCR analysis of
nt for 24 h. As previously observed, an additive effect of IL1β can be observed. *p b 0.05;
sed as a loading control. *p b 0.05 vs 5.5 mM. Results are mean ± sem of 6 independent
Fig. 7. Increased prolactinemia in obese subjects. (A) prolactinemia, evaluated in lean and
obese rats, demonstrated a 3 fold increase in obese animals. *p b 0.05 vs control (lean).
Results are means ± sem of 5 independent experiments, ANOVA with Bonferroni correc-
tion. (B) Prolactinemia, assayed in the serum of lean and obese subject with different
glycemic status showed a tendency to increasewith obesity. The signiﬁcant additive effect
of hyperglycemia can be observed in OBPreD samples. *p b 0.05. In OBD subjects, no
statistical signiﬁcance was achieved probably due to the antidiabetic treatment received
by these patients. Results are means ± sem of 6 independent experiments, ANOVA with
Bonferroni correction.
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with pro-inﬂammatory cytokines, such as IL1β, induces a prolactin ex-
pression per se, conﬁrming the observations previously made in the
transgenic rat model [38]. In our study, Pit-1, the PRL-speciﬁc transcrip-
tion factor has been found expressed in the macrophages of rat and
human origin. The kinetic of Pit-1 expression is parallel to the one of
PRL showing that, in our model, the PRL expression is due (at least
partly) to the increased expression of Pit-1. Some papers reported that
Pit-1 expression is induced by cAMP/PKA or PKC action and subsequent
phosphorylation of protein implicated in the signaling pathway. Unpub-
lished data generated in our laboratory demonstrated that treatment of
puriﬁed populations of macrophages in the same culture conditions
(with different glucose concentrations; with or without IL1β (an inhib-
itor of PI3 kinase))was blocking the increased expression of Pit-1 and as
a consequence, the PRL expression (data not shown).
We observed also that rat peritoneal macrophages, non stimulated
by thioglycollate injection, but placed in the same culture conditions
as the ATMor the THP-1, also respond to elevated concentrations of glu-
cose and inﬂammation by increasing prolactin expression (unpublished
data). It appears that the mechanism of prolactin secretion is occurring
in all populations of macrophages regardless of their tissue location.
The effect of elevated glucose on macrophages, as observed during
diabetes, has been evaluated in many papers over the recent years
[39]. Wen et al. demonstrated that high glucose treatment of mouse
peritoneal macrophages induces, in a time- and dose-dependent man-
ner, the expression (N2× compared to control) of IL1β and numerous
other pro-inﬂammatory cytokines [40]. In vivo experiments on diabetic
db/db mice conﬁrmed the observations made in vitro on the increased
expression of IL1β. Moreover, Dasu et al. [41], using human monocytic
THP-1 cells, demonstrated that high-glucose treatment (15 mmol/Lfor 24 h) induces the expression of the Toll-Like Receptors TLR2
and TLR4 leading to the activation of the MyD88-mediated signaling
pathway and the nuclear translocation of NFkB. Data generated by
our group on isolated placental macrophages demonstrated that mild
(300 mg/dl) or severe (N500 mg/dl) hyperglycemia, during gestation,
induced an early activation of the pro-inﬂammatory genes mediated
by the TLR2/TLR4 pathway [39].
Prolactin, as an endocrine hormone, is released in the blood stream.
The prolactinemia, evaluated in our rat and human samples follow the
same pattern as observed for prolactin mRNA expression. Even through
some studies carried out in humans, didn't show any modiﬁcations in
prolactinemia in obesity [42], our experiments in rats and humans com-
bined with previous published studies of other groups demonstrated a
signiﬁcant increase with obesity. Observations made in mildly obese
women detected an enhanced prolactin secretion across the 24 hour
cycle (compared to normal-weight women) [28]. After subsequent
weight loss (by a low calorie diet or bariatric surgery), the 24 h circadi-
an prolactin release in obese women was reduced clearly demonstrat-
ing that increased prolactin levels are a consequence rather than a
cause of obesity [29,43].
Prolactin has many effects in animals and humans and is known to
regulate seasonal and non-seasonal fat mass in different species, like
birds,ﬁsh andmammals [44,45]. Based on our observations, we hypoth-
esize that the inﬁltrating macrophages, in a pro-inﬂammatory environ-
ment, will locally release prolactin which could stimulate immune cells
and worsening obesity. This vicious cycle could be responsible to the
maintenance of obesity in patients. Genome-wide association studies
revealed that a common variant adjacent to the prolactin gene is posi-
tively associated with obesity in males [46], reinforcing the potential
importance of prolactin on obesity. In adipose tissue samples from
obese patients, we observed an increased expression of prolactin at
mRNA and protein levels and also at plasmatic level when obesity was
complicatedwith diabetes. Surprisingly, the higher prolactin expression
was observed in Obese Pre Diabetic patients and not in Obese Diabetic
patients. This could be explained by the fact that only Obese Diabetic
patients received antidiabetic drugs (mainly metformin and insulin)
reducing their hyperglycemia. As demonstrated in this paper, hypergly-
cemia, per se, is inducing prolactin expression by the macrophages. We
can hypothesize that antidiabetic drugs given to the Obese Diabetic
patients will normalize glycemia and then naturally reduce prolactin
expression by the macrophages. This observation is reinforcing the
additive effect of hyperglycemia and inﬂammation on prolactin expres-
sion by the macrophages observed in isolated ATM and THP-1.
In conclusion, our ﬁndings provide new insight into the potential in-
volvement of the macrophages in obesity, diabetes and diabesity. We
demonstrated that macrophages, stimulated by high glucose and/or in-
ﬂammation, are synthesizing prolactin that participates in the increased
prolactinemia observed in obese patients. The additive effect of high
glucose and inﬂammation on the prolactin expression is of great inter-
est for the treatment of obese diabetic patients. Combining antidiabetic
medications with prolactin-reducing therapies could provide a new
approach for obesity treatment.
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